Last checked at 15 Nov 2022 09:58
LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades1,487
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,971.00
Bid:
1,971.00
Ask:
1,972.00
Change:
-29.00 (-1.45%)
Spread:
1.00 (0.051%)
Open:
2,008.00
High:
2,012.00
Low:
1,958.00
Prev. Close:
2,000.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Hikma to suspend production in New Jersey
Fri, 02nd Nov 2012 07:29
Hikma Pharmaceuticals is considering the future of its Generics business as its Eatontown facility in New Jersey continues to be dogged by compliance issues. The group has opted to halt commercial production of generic drugs at Eatontown facility in the US until mid-January while it gets to grips with compliance issues raised by the Food & Drug Administration (FDA)."We will continue to supply our customers to the best of our ability through existing inventory and from our FDA approved manufacturing facilities in the Middle East and North Africa region," the company said. The group now expects the Generics division to deliver revenue of around $105m and a loss of around $15m, compared to our previous guidance of break-even. This includes around $5m of non-recurring costs related to remediation and restructuring. The group is reviewing this business and is considering all strategic options.Things are going a lot better elsewhere in the group, with the Branded division performing well and the Injectables business performing ahead of expectations.The group continues to expect around 20% Branded revenue growth for the full year. Excluding adverse currency movements, which are likely to have a small negative impact on margins, Hikma expects Branded gross margin and adjusted operating margin to be broadly in line with 2011. The strong showing by the global Injectables business has been driven by new product launches, increased tender sales, better portfolio management and increased demand owing to continuing product shortages in the US market, Hikma said. Over the full year, Hikma now expects to exceed its previous guidance, with revenue of around $460m and adjusted earnings before interest and tax (EBIT) margin above 22%."We are committed to bringing our Eatontown facility back into full compliance as quickly as possible. More broadly, we are continuing to benefit from the strength of our diversified business model - our Branded business is performing well and our Injectables business is exceeding our expectations," said Said Darwazah, Chief Executive Officer of Hikma."We are pleased to maintain our guidance for 2012 of around 20% group revenue growth," the statement added.
More News
14 Nov 2022 09:25
LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more8 Nov 2022 09:39
LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more3 Nov 2022 11:17
Hikma Pharmaceuticals reiterates 2022 guidance as costs widen
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.
Read more3 Nov 2022 11:08
3 Nov 2022 09:28
Banks, insurance dodge carnage as real estate stocks sink
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .
Read more3 Nov 2022 09:18
LONDON MARKET OPEN: BT results disappoint; pound falls on Fed outlook
(Alliance News) - Stock prices in London opened lower on Thursday, as the pound fell against a strengthening dollar, after the Federal Reserve indicated that US interest rates are likely to reach higher levels than previously thought.
Read more3 Nov 2022 08:39
Hikma reiterates FY guidance amid 'strong momentum'
(Sharecast News) - Drugmaker Hikma Pharmaceuticals reiterated full-year guidance on Thursday, citing "strong momentum" in its injectables and branded units, but also cautioned that had begun to see the effects of the global inflationary environment on costs.
Read more3 Nov 2022 07:59
LONDON BRIEFING: Stocks called down as markets brace for BoE hike
(Alliance News) - Stocks in London are set to open lower on Thursday, as the pressure is on for the Bank of England at midday, after the US Federal Reserve indicated interest rates are likely to have to reach a higher level than previously expected.
Read more4 Oct 2022 09:24
LONDON BROKER RATINGS: Upgrades for Vodafone, AJ Bell, B&M, Pennon
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more4 Oct 2022 08:46
Berenberg initiates coverage on Hikma Pharmaceuticals at 'hold'
(Sharecast News) - Analysts at Berenberg initiated coverage on drugmaker Hikma Pharmaceuticals at 'hold' on Tuesday, stating it was "waiting for the tide to turn".
Read more4 Oct 2022 07:52
LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility
(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.
Read more30 Sep 2022 11:08
IN BRIEF: Hikma addresses gender imbalance with two new non-executives
Hikma Pharmaceuticals PLC - London-based pharmaceutical company - Appoints Laura Balan and Victoria Hull as independent non-executive directors with effect from October 1 and November 1, respectively. Balan worked for 17 years at the Capital Group Co, where she covered European healthcare and pharmaceutical sectors. Hull is currently a non-executive director for IQE PLC, Alphaware IP Group PLC and Network International Holdings PLC. Previously she was chief legal officer & executive director at Invensys PLC, now Schneider Electric, from 2001 to 2014.
Read more15 Sep 2022 09:30
LONDON BROKER RATINGS: Credit Suisse cuts AstraZeneca and raises GSK
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Friday:
Read more12 Sep 2022 15:55
UK dividends calendar - next 7 days
| Tuesday 13 September | |
| Lindsell Train Investment Trust PLC | dividend payment date |
| Ibstock PLC | dividend payment date |
| Wednesday 14 September | |
| Fresnillo PLC | dividend payment date |
| Reckitt Benckiser Group PLC | dividend payment date |
| Thursday 15 September | |
| Artemis Alpha Trust PLC | ex-dividend date |
| Bakkavor Group PLC | ex-dividend date |
| Brunner Investment Trust PLC | dividend payment date |
| Cairn Homes PLC | ex-dividend date |
| Capital & Regional PLC | ex-dividend date |
| Energean PLC | ex-dividend date |
| Genel Energy PLC | ex-dividend date |
| Goodwin PLC | ex-dividend date |
| Henderson High Income Trust PLC | ex-dividend date |
| Highcroft Investments PLC | ex-dividend date |
| Honeycomb Investment Trust PLC | ex-dividend date |
| International Public Partnerships Ltd | ex-dividend date |
| Intertek Group PLC | ex-dividend date |
| Irish Continental Group PLC | ex-dividend date |
| JPMorgan Global Emerging Inc Trust | ex-dividend date |
| Luceco PLC | ex-dividend date |
| Macfarlane Group PLC | ex-dividend date |
| Melrose Industries PLC | ex-dividend date |
| Midwich Group PLC | ex-dividend date |
| Murray Income Trust PLC | dividend payment date |
| Restore PLC | ex-dividend date |
| RPS Group PLC | ex-dividend date |
| ThomasLloyd Energy Impact Trust PLC | ex-dividend date |
| Trifast PLC | ex-dividend date |
| Triple Point Social Housing REIT PLC | ex-dividend date |
| Unite Group PLC | ex-dividend date |
| Friday 16 September | |
| 4imprint Group PLC | dividend payment date |
| abrdn Asia Focus PLC | dividend payment date |
| Baillie Gifford UK Growth Trust PLC | dividend payment date |
| Barclays PLC | dividend payment date |
| Clarkson PLC | dividend payment date |
| Currys PLC | dividend payment date |
| Halfords Group PLC | dividend payment date |
| IMI PLC | dividend payment date |
| LSL Property Services PLC | dividend payment date |
| Montanaro European Smaller Companies Trust PLC | dividend payment date |
| NatWest Group PLC | dividend payment date |
| NatWest Group PLC | special dividend date |
| Pershing Square Holdings Ltd | dividend payment date |
| Redcentric PLC | dividend payment date |
| Spirent Communications PLC | dividend payment date |
| TI Fluid Systems PLC | dividend payment date |
| Vesuvius PLC | dividend payment date |
| VH Global Sustainable Energy Opportunities PLC | dividend payment date |
| Witan Investment Trust PLC | dividend payment date |
| Monday 19 September | |
| Capital & Counties Properties PLC | dividend payment date |
| Hikma Pharmaceuticals PLC | dividend payment date |
| IP Group PLC | dividend payment date |
| Pearson PLC | dividend payment date |
| Quilter PLC | dividend payment date |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |